![“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800.jpg?w=350&fit=crop&auto=format)
“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.
|Poll|August 13, 2012
Enlarging Scalp Nodules on 56-Year-Old Patient
Author(s)Ted Rosen, MD
Advertisement
A 56-year-old Caucasian male presented with an approximately 25-year history of gradually enlarging, asymptomatic scalp nodules. His father, unavailable for examination due to his death in an auto accident decades earlier, had a nearly lifelong history of many 2-mm to 3-mm flesh-colored papules both in his nasolabial folds and on his upper lip. The patient’s sister had similar scalp nodules. Results of a recent routine laboratory panel were entirely normal. One medium-sized nodule was removed by deep shave biopsy and submitted for histologic examination. It demonstrated large, lobulated nests of basaloid cells arranged in a jigsaw puzzle pattern.
This patient is at risk for developing which of the following?
Advertisement
Related to this article
Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.
At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.
Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.
Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
2
EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma
3
FDA OKs Pirtobrutinib in Frontline CLL/SLL
4
How Well Does Radiotherapy Pair With Dual PD-1/LAG-3 Blockade in NSCLC?
5